{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T22:49:38Z","timestamp":1789080578210,"version":"build-2803163510"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"DOI":"10.1186\/s12985-025-02623-y","type":"journal-article","created":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T16:59:10Z","timestamp":1736960350000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Impact of antiviral prophylaxis on EBV viremia and posttransplant lymphoproliferative disorders in solid organ transplant recipients: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0459-1042","authenticated-orcid":false,"given":"Marjan","family":"Moghadamnia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khadijeh","family":"Delroba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shima","family":"Heidari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Rezaie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2004-7845","authenticated-orcid":false,"given":"Simin","family":"Dashti-Khavidaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,15]]},"reference":[{"key":"2623_CR1","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/hon.3139","volume":"41","author":"TG Gross","year":"2023","unstructured":"Gross TG, Rubinstein JD. Post-transplant lymphoproliferative disease in children, adolescents, and young adults. Hematol Oncol. 2023;41:48\u201356.","journal-title":"Hematol Oncol"},{"issue":"9","key":"2623_CR2","doi-asserted-by":"publisher","first-page":"e13652","DOI":"10.1111\/ctr.13652","volume":"33","author":"UD Allen","year":"2019","unstructured":"Allen UD, Preiksaitis JK. Post\u2010transplant lymphoproliferative disorders, Epstein\u2010Barr virus infection, and disease in solid organ transplantation: guidelines from the American Society of Transplantation infectious diseases community of practice. Clin Transplant. 2019;33(9):e13652. https:\/\/doi.org\/10.1111\/ctr.13652.","journal-title":"Clin Transplant"},{"issue":"3","key":"2623_CR3","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1111\/ajt.14020","volume":"17","author":"M AlDabbagh","year":"2017","unstructured":"AlDabbagh M, Gitman M, Kumar D, Humar A, Rotstein C, Husain S. The role of antiviral prophylaxis for the prevention of epstein\u2013barr virus\u2013associated posttransplant lymphoproliferative disease in solid organ transplant recipients: a systematic review. Am J Transplant. 2017;17(3):770\u201381.","journal-title":"Am J Transplant"},{"issue":"Supplement_1","key":"2623_CR4","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1093\/jpids\/piad097","volume":"13","author":"M Yamada","year":"2024","unstructured":"Yamada M, L\u2019Huillier AG, Green M. A focused review of epstein-barr virus infections and PTLD in pediatric transplant recipients: guidance from the IPTA and ECIL guidelines. J Pediatr Infect Dis Soc. 2024;13(Supplement_1):S31\u20138. https:\/\/doi.org\/10.1093\/jpids\/piad097.","journal-title":"J Pediatr Infect Dis Soc"},{"key":"2623_CR5","doi-asserted-by":"publisher","first-page":"1087864","DOI":"10.3389\/fped.2022.1087864","volume":"10","author":"R Fulchiero","year":"2022","unstructured":"Fulchiero R, Amaral S. Post-transplant lymphoproliferative disease after pediatric kidney transplant. Front Pediatr. 2022;10:1087864.","journal-title":"Front Pediatr"},{"issue":"12","key":"2623_CR6","doi-asserted-by":"publisher","first-page":"2894","DOI":"10.1111\/j.1600-6143.2005.01115.x","volume":"5","author":"DP Funch","year":"2005","unstructured":"Funch DP, Walker AM, Schneider G, Ziyadeh NJ, Pescovitz MD. Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients. Am J Transplant. 2005;5(12):2894\u2013900.","journal-title":"Am J Transplant"},{"issue":"5","key":"2623_CR7","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/tri.13085","volume":"31","author":"S Ville","year":"2018","unstructured":"Ville S, Imbert-Marcille BM, Coste-Burel M, Garandeau C, Meurette A, Cantarovitch D, et al. Impact of antiviral prophylaxis in adults Epstein-Barr virus-seronegative kidney recipients on early and late post-transplantation lymphoproliferative disorder onset: a retrospective cohort study. Transpl Int. 2018;31(5):484\u201394.","journal-title":"Transpl Int"},{"issue":"7","key":"2623_CR8","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1111\/j.1432-2277.2012.01485.x","volume":"25","author":"B H\u00f6cker","year":"2012","unstructured":"H\u00f6cker B, B\u00f6hm S, Fickenscher H, K\u00fcsters U, Schnitzler P, Pohl M, et al. (Val-) Ganciclovir prophylaxis reduces Epstein-Barr virus primary infection in pediatric renal transplantation. Transpl Int. 2012;25(7):723\u201331.","journal-title":"Transpl Int"},{"key":"2623_CR9","doi-asserted-by":"publisher","first-page":"1085101","DOI":"10.3389\/fped.2022.1085101","volume":"10","author":"E Cheyssac","year":"2023","unstructured":"Cheyssac E, Savadogo H, Lagoutte N, Baudouin V, Charbit M, Novo R, et al. Valganciclovir is not associated with decreased EBV infection rate in pediatric kidney transplantation. Front Pediatr. 2023;10:1085101.","journal-title":"Front Pediatr"},{"issue":"7","key":"2623_CR10","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1111\/ajt.16423","volume":"21","author":"LN Walti","year":"2021","unstructured":"Walti LN, Mugglin C, Sidler D, Mombelli M, Manuel O, Hirsch HH, et al. Association of antiviral prophylaxis and rituximab use with posttransplant lymphoproliferative disorders (PTLDs): a nationwide cohort study. Am J Transpl. 2021;21(7):2532\u201342.","journal-title":"Am J Transpl"},{"issue":"9","key":"2623_CR11","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1111\/tri.13982","volume":"34","author":"A Blazquez-Navarro","year":"2021","unstructured":"Blazquez-Navarro A, Dang-Heine C, Wehler P, Roch T, Bauer C, Neumann S, et al. Risk factors for Epstein-Barr virus reactivation after renal transplantation: results of a large, multi-centre study. Transpl Int. 2021;34(9):1680\u20138.","journal-title":"Transpl Int"},{"key":"2623_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"2623_CR13","unstructured":"Jpt H. Cochrane handbook for systematic reviews of interventions. http:\/\/www.cochrane-handbook.org. 2008."},{"issue":"3","key":"2623_CR14","doi-asserted-by":"publisher","first-page":"A12","DOI":"10.7326\/ACPJC-1995-123-3-A12","volume":"123","author":"WS Richardson","year":"1995","unstructured":"Richardson WS, Wilson MC, Nishikawa J, Hayward RS. The well-built clinical question: a key to evidence-based decisions. ACP J Club. 1995;123(3):A12\u20133.","journal-title":"ACP J Club"},{"issue":"4","key":"2623_CR15","first-page":"420","volume":"106","author":"MB Eriksen","year":"2018","unstructured":"Eriksen MB, Frandsen TF. The impact of patient, intervention, comparison, outcome (PICO) as a search strategy tool on literature search quality: a systematic review. J Med Lib Assoc: JMLA. 2018;106(4):420.","journal-title":"J Med Lib Assoc: JMLA"},{"issue":"7414","key":"2623_CR16","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360.","journal-title":"BMJ"},{"issue":"3","key":"2623_CR17","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177\u201388.","journal-title":"Control Clin Trials"},{"key":"2623_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"key":"2623_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","author":"JAC Sterne","year":"2016","unstructured":"Sterne JAC, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016. https:\/\/doi.org\/10.1136\/bmj.i4919.","journal-title":"BMJ"},{"issue":"2","key":"2623_CR20","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.1399-3046.2006.00641.x","volume":"11","author":"L Li","year":"2007","unstructured":"Li L, Chaudhuri A, Weintraub LA, Hsieh F, Shah S, Alexander S, et al. Subclinical cytomegalovirus and Epstein-Barr virus viremia are associated with adverse outcomes in pediatric renal transplantation. Pediatr Transplant. 2007;11(2):187\u201395.","journal-title":"Pediatr Transplant"},{"issue":"6","key":"2623_CR21","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1097\/00007890-199709270-00010","volume":"64","author":"IA Darenkov","year":"1997","unstructured":"Darenkov IA, Marcarelli MA, Basadonna GP, Friedman AL, Lorber KM, Howe JG, et al. REDUCED INCIDENCE OF EPSTEIN-BARR VIRUS-ASSOCIATED POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER USING PREEMPTIVE ANTIVIRAL THERAPY1. Transplantation. 1997;64(6):848\u201352.","journal-title":"Transplantation"},{"issue":"2","key":"2623_CR22","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1155\/1993\/845236","volume":"4","author":"WF Schlech III","year":"1993","unstructured":"Schlech WF III, Meagher N, Cohen AD, Belitsky P, MacDonald A, LeBlanc JC. A randomized double-blind placebo controlled trial of oral acyclovir in renal allograft recipients. Can J Infect Dis Med Microbiol. 1993;4(2):84\u20138.","journal-title":"Can J Infect Dis Med Microbiol"},{"issue":"2","key":"2623_CR23","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.TP.0000128611.71038.0C","volume":"78","author":"JY Wong","year":"2004","unstructured":"Wong JY, Tait B, Levvey B, Griffiths A, Esmore DS, Snell GI, et al. Epstein-Barr virus primary mismatching and HLA matching: key risk factors for post lung transplant lymphoproliferative disease. Transplantation. 2004;78(2):205\u201310.","journal-title":"Transplantation"},{"issue":"5","key":"2623_CR24","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/S1053-2498(01)00407-7","volume":"21","author":"MA Malouf","year":"2002","unstructured":"Malouf MA, Chhajed PN, Hopkins P, Plit M, Turner J, Glanville AR. Anti-viral prophylaxis reduces the incidence of lymphoproliferative disease in lung transplant recipients. J Heart Lung Transplant. 2002;21(5):547\u201354.","journal-title":"J Heart Lung Transplant"},{"issue":"5","key":"2623_CR25","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1038\/s41390-019-0523-4","volume":"87","author":"S Albatati","year":"2020","unstructured":"Albatati S, Sharma A, Haubrich K, Wright A, Gantt S, Blydt-Hansen TD. Valganciclovir prophylaxis delays onset of EBV viremia in high-risk pediatric solid organ transplant recipients. Pediatr Res. 2020;87(5):892\u20136.","journal-title":"Pediatr Res"},{"issue":"6","key":"2623_CR26","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.healun.2010.01.013","volume":"29","author":"C Manlhiot","year":"2010","unstructured":"Manlhiot C, Pollock-BarZiv SM, Holmes C, Weitzman S, Allen U, Clarizia NA, et al. Post-transplant lymphoproliferative disorder in pediatric heart transplant recipients. J Heart Lung Transplant. 2010;29(6):648\u201357.","journal-title":"J Heart Lung Transplant"},{"key":"2623_CR27","doi-asserted-by":"publisher","first-page":"669","DOI":"10.4414\/smw.2007.11961","volume":"37","author":"O Manuel","year":"2007","unstructured":"Manuel O, Venetz JP, Sturzenegger N, Fontana M, Meylan PR. Efficacy and safety of universal valganciclovir prophylaxis combined with a tacrolimus\/mycophenolate-based regimen in kidney transplantation. Swiss Med Wkly. 2007;37:669. https:\/\/doi.org\/10.4414\/smw.2007.11961.","journal-title":"Swiss Med Wkly"},{"issue":"3","key":"2623_CR28","doi-asserted-by":"publisher","first-page":"e14848","DOI":"10.1111\/ctr.14848","volume":"37","author":"LN Van Aelst","year":"2023","unstructured":"Van Aelst LN, Droogn\u00e9 W, V\u00f6r\u00f6s G, Van Cleemput J. Combination prophylaxis in CMV high risk heart transplant recipients: a single center experience. Clin Transplant. 2023;37(3):e14848.","journal-title":"Clin Transplant"},{"issue":"9","key":"2623_CR29","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1097\/00007890-199905150-00002","volume":"67","author":"S Birkeland","year":"1999","unstructured":"Birkeland S, Andersen H, Hamilton-Dutoit SJ. PREVENTING ACUTE REJECTION, EPSTEIN-BARR VIRUS INFECTION, AND POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDERS AFTER KIDNEY TRANSPLANTATION: USE OF ACICLOVIR AND MYCOPHENOLATE MOFETIL IN A STEROID-FREE IMMUNOSUPPRESSIVE PROTOCOL1. Transplantation. 1999;67(9):1209\u201314.","journal-title":"Transplantation"},{"issue":"8","key":"2623_CR30","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1111\/tri.12342","volume":"27","author":"N Halliday","year":"2014","unstructured":"Halliday N, Smith C, Atkinson C, O\u2019Beirne J, Patch D, Burroughs AK, et al. Characteristics of Epstein-Barr viraemia in adult liver transplant patients: A retrospective cohort study. Transpl Int. 2014;27(8):838\u201346.","journal-title":"Transpl Int"},{"key":"2623_CR31","first-page":"426","volume":"13","author":"M Aliakbarian","year":"2015","unstructured":"Aliakbarian M, Dehghani SM, Geramizadeh B, Nikeghbalian S, Kasiri K, Kazemi K, et al. Prevention of posttransplant lymphoproliferative disorder in pediatric patients with a liver transplant. Exp Clin Transplant. 2015;13:426\u20139.","journal-title":"Exp Clin Transplant"},{"issue":"4","key":"2623_CR32","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1097\/TP.0000000000001531","volume":"101","author":"E Nicastro","year":"2017","unstructured":"Nicastro E, Giovannozzi S, Stroppa P, Casotti V, Callegaro AP, Tebaldi A, et al. Effectiveness of preemptive therapy for cytomegalovirus disease in pediatric liver transplantation. Transplantation. 2017;101(4):804\u201310.","journal-title":"Transplantation"},{"key":"2623_CR33","doi-asserted-by":"crossref","unstructured":"Kim JM, Lee SK, Kim SJ, Joh JW, Kwon CH, Choe YH, Shin M, Kim EY, Moon JI, Jung GO, Choi GS. Risk factors for posttransplant lymphoproliferative disorder in pediatric liver transplant recipients with cytomegalovirus antigenemia. InTransplantation proceedings 2010 Apr 1 (Vol. 42, No. 3, pp. 895-899). Elsevier.","DOI":"10.1016\/j.transproceed.2010.02.042"},{"issue":"11","key":"2623_CR34","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/j.healun.2007.08.010","volume":"26","author":"MG Crespo-Leiro","year":"2007","unstructured":"Crespo-Leiro MG, Alonso-Pulp\u00f3n L, Ariz\u00f3n JM, Almenar L, Delgado JF, Palomo J, et al. Influence of induction therapy, immunosuppressive regimen and anti-viral prophylaxis on development of lymphomas after heart transplantation: data from the spanish post\u2013heart transplant tumour registry. J Heart Lung Transplant. 2007;26(11):1105\u20139.","journal-title":"J Heart Lung Transplant"},{"issue":"8","key":"2623_CR35","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1097\/TP.0b013e3181b9692d","volume":"88","author":"G Opelz","year":"2009","unstructured":"Opelz G, Daniel V, Naujokat C, D\u00f6hler B. Epidemiology of pretransplant EBV and CMV serostatus in relation to posttransplant non-Hodgkin lymphoma. Transplantation. 2009;88(8):962\u20137.","journal-title":"Transplantation"},{"issue":"2","key":"2623_CR36","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/ajh.21911","volume":"86","author":"SC Quinlan","year":"2011","unstructured":"Quinlan SC, Pfeiffer RM, Morton LM, Engels EA. Risk factors for early-onset and late-onset post-transplant lymphoproliferative disorder in US kidney recipients. Am J Hematol. 2011;86(2):206.","journal-title":"Am J Hematol"},{"issue":"2","key":"2623_CR37","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1053\/j.ajkd.2021.01.015","volume":"78","author":"B Sprangers","year":"2021","unstructured":"Sprangers B, Riella LV, Dierickx D. Posttransplant lymphoproliferative disorder following kidney transplantation: a review. Am J Kidney Dis. 2021;78(2):272\u201381.","journal-title":"Am J Kidney Dis"},{"key":"2623_CR38","doi-asserted-by":"publisher","first-page":"116270","DOI":"10.1016\/j.bcp.2024.116270","volume":"10","author":"M Pociupany","year":"2024","unstructured":"Pociupany M, Snoeck R, Dierickx D, Andrei G. Treatment of Epstein-Barr Virus infection in immunocompromised patients. Biochem Pharmacol. 2024;10:116270.","journal-title":"Biochem Pharmacol"},{"issue":"12","key":"2623_CR39","first-page":"1161","volume":"17","author":"SD Zangwill","year":"1998","unstructured":"Zangwill SD, Hsu DT, Kichuk MR, Garvin JH, Stolar C, Haddad J Jr, et al. Incidence and outcome of primary Epstein-Barr virus infection and lymphoproliferative disease in pediatric heart transplant recipients. J Heart Lung Transplant. 1998;17(12):1161\u20136.","journal-title":"J Heart Lung Transplant"},{"issue":"1","key":"2623_CR40","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41392-020-00376-4","volume":"6","author":"Y Cao","year":"2021","unstructured":"Cao Y, Xie L, Shi F, Tang M, Li Y, Hu J, Zhao L, Zhao L, Yu X, Luo X, Liao W. Targeting the signaling in Epstein-Barr virus-associated diseases: mechanism, regulation, and clinical study. Signal Transduct Target Ther. 2021;6(1):15.","journal-title":"Signal Transduct Target Ther"},{"issue":"7","key":"2623_CR41","first-page":"983","volume":"139","author":"K Toner","year":"2022","unstructured":"Toner K, Bollard CM. EBV+ lymphoproliferative diseases: opportunities for leveraging EBV as a therapeutic target. Blood J Am Soc Hematol. 2022;139(7):983\u201394.","journal-title":"Blood J Am Soc Hematol"},{"issue":"7","key":"2623_CR42","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1097\/00007890-199904150-00023","volume":"67","author":"DL Kogan","year":"1999","unstructured":"Kogan DL, Burroughs M, Emre S, Fishbein T, Moscona A, Ramson C, et al. Prospective longitudinal analysis of quantitative Epstein-Barr virus polymerase chain reaction in pediatric liver transplant recipients. Transplantation. 1999;67(7):1068\u201370.","journal-title":"Transplantation"},{"issue":"3","key":"2623_CR43","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1097\/00007890-200208150-00013","volume":"74","author":"RD Holmes","year":"2002","unstructured":"Holmes RD, Orban-Eller K, Karrer FR, Rowe DT, Narkewicz MR, Sokol RJ. Response of elevated Epstein-Barr virus DNA levels to therapeutic changes in pediatric liver transplant patients: 56-month follow up and outcome. Transplantation. 2002;74(3):367\u201372.","journal-title":"Transplantation"},{"key":"2623_CR44","doi-asserted-by":"crossref","unstructured":"\u00d6z\u00e7ay F, Arslan H, Bilezik\u00e7i B, Sevmi\u015f \u015e, Moray G, Haberal M. The role of valacyclovir on Epstein\u2013Barr virus viral loads in pediatric liver transplantation patients. InTransplantation proceedings 2009 Sep 1 (Vol. 41, No. 7, pp. 2878-2880). Elsevier.","DOI":"10.1016\/j.transproceed.2009.07.059"},{"issue":"1","key":"2623_CR45","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1097\/TXD.0000000000000557","volume":"2","author":"ML Nijland","year":"2016","unstructured":"Nijland ML, Kersten MJ, Pals ST, Bemelman FJ, Ten Berge IJ. Epstein-Barr virus\u2013positive posttransplant lymphoproliferative disease after solid organ transplantation: pathogenesis, clinical manifestations, diagnosis, and management. Transplant Direct. 2016;2(1):e48.","journal-title":"Transplant Direct"},{"issue":"9","key":"2623_CR46","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1097\/TP.0000000000002146","volume":"102","author":"AC Peters","year":"2018","unstructured":"Peters AC, Akinwumi MS, Cervera C, Mabilangan C, Ghosh S, Lai R, et al. The changing epidemiology of posttransplant lymphoproliferative disorder in adult solid organ transplant recipients over 30 years: a single-center experience. Transplantation. 2018;102(9):1553\u201362.","journal-title":"Transplantation"},{"issue":"8","key":"2623_CR47","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1086\/466529","volume":"192","author":"RR Razonable","year":"2005","unstructured":"Razonable RR, Brown RA, Humar A, Covington E, Alecock E, Paya CV. Herpesvirus infections in solid organ transplant patients at high risk of primary cytomegalovirus disease. J Infect Dis. 2005;192(8):1331\u20139.","journal-title":"J Infect Dis"},{"issue":"6","key":"2623_CR48","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1086\/516139","volume":"25","author":"M Green","year":"1997","unstructured":"Green M, Kaufmann M, Wilson J, Reyes J. Comparison of intravenous ganciclovir followed by oral acyclovir with intravenous ganciclovir alone for prevention of cytomegalovirus and Epstein-Barr virus disease after liver transplantation in children. Clin Infect Dis. 1997;25(6):1344\u20139.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"2623_CR49","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1097\/00007890-199812270-00006","volume":"66","author":"SV McDiarmid","year":"1998","unstructured":"McDiarmid SV, Jordan S, Lee GS, Toyoda M, Goss JA, Vargas JH, et al. Prevention and Preemptive Therapy of Posttransplant Lymphoproliferative Disease in Pediatric Liver Recipients1. Transplantation. 1998;66(12):1604\u201311.","journal-title":"Transplantation"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-025-02623-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-025-02623-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-025-02623-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T16:59:14Z","timestamp":1736960354000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-025-02623-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,15]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2623"],"URL":"https:\/\/doi.org\/10.1186\/s12985-025-02623-y","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,15]]},"assertion":[{"value":"10 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval and consent to participate.Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is authors\u2019 own work and does not need consent for publication from third party. All authors agree with its publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare no competing interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"11"}}